BLA 022575 · Shire Human Genetic
Vpriv
Velaglucerase Alfa · Intravenous · Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Feb 26, 2010
Approved uses
2
Original approval plus efficacy supplements
Registered trials
14
8 Phase 3, 0 recruiting
FAERS reports
2,052
1,718 serious, 280 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement and after extended duration of therapy. Initiate VPRIV in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VPRIV and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS See full...
What it is approved for
From the label in effect Nov 26, 2024.
VPRIV is indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease. VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease. ( 1 )
Mechanism: Gaucher disease is an autosomal recessive disorder caused by mutations in the GBA gene, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. Glucocerebrosidase catalyzes the conversion of the sphingolipid glucocerebroside into glucose and ceramide. The enzymatic deficiency causes an accumulation of glucocerebroside primarily in the lysosomal compartment of macrophages, giving rise to foam cells or "Gaucher cells". Velaglucerase alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside. In clinical trials VPRIV reduced...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 21, 2013 Supplement 12 · Efficacy OrphanLetterLabel
- Feb 26, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
2 products under this application
- VPRIV · VELAGLUCERASE ALFA 400 UNITS/VIAL · INJECTABLE, INTRAVENOUS · Prescription
- VPRIV · VELAGLUCERASE ALFA 200 UNITS/VIAL · POWDER, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Velaglucerase Alfa" as an intervention, any sponsor and status, largest first.
- An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher DiseasePivotal-lookingCompleted
ShireTakeda (TAK)
NCT00635427 · 95 participants · Start Mar 13, 2008 · Primary completion Dec 28, 2012
Drug: VPRIV® · For: Gaucher Disease, Type 1
Sites: Los Angeles, California; Oakland, California; Atlanta, Georgia · 21 sites in all
- Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With ImiglucerasePivotal-lookingCompleted
ShireTakeda (TAK)
NCT00478647 · 40 participants · Start Jul 25, 2007 · Primary completion Jun 26, 2009
Drug: GA-GCB (velaglucerase alfa) · For: Gaucher Disease
Sites: Los Angeles, California; Oakland, California; Decatur, Georgia · 15 sites in all
- Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher DiseasePivotal-lookingCompleted
ShireTakeda (TAK)
NCT00553631 · 34 participants · Start Jan 29, 2008 · Primary completion May 5, 2009
Drug: velaglucerase alfa; imiglucerase · For: Gaucher Disease, Type 1
Sites: Durham, North Carolina; Buenos Aires, Argentina; Calicut, India · 11 sites in all
- A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher DiseasePivotal-lookingCompleted
ShireTakeda (TAK)
NCT00430625 · 25 participants · Start Feb 15, 2007 · Primary completion Apr 1, 2009
Drug: VPRIV ®, · For: Gaucher Disease, Type 1
Sites: Buenos Aires, Argentina; Jerusalem, Israel; Asunción, Paraguay · 5 sites in all
ShireTakeda (TAK)
NCT02574286 · 21 participants · Start Jun 29, 2016 · Primary completion Nov 12, 2020
Drug: Velaglucerase alfa · For: Gaucher Disease
Sites: Beverly Hills, California; Los Angeles, California; Atlanta, Georgia · 15 sites in all
- A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseasePivotal-lookingCompleted
TakedaTakeda (TAK)
NCT05529992 · 20 participants · Start Jan 3, 2023 · Primary completion Aug 5, 2024
Drug: Velaglucerase Alfa · For: Gaucher Disease
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 10 sites in all
Shaare Zedek Medical CenterAcademic, hospital or other
NCT04120506 · 15 participants · Start Jan 10, 2016 · Primary completion Jan 20, 2017
Drug: VPRIV · For: Gaucher Disease, Type 1
Shaare Zedek Medical CenterAcademic, hospital or other
NCT03702361 · 15 participants · Start Sep 4, 2018 · Primary completion Sep 30, 2019
Drug: VPRIV · For: Primary Disease
Sites: Jerusalem, Israel
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- inappropriate schedule of product administration212
- product dose omission issue198
- covid-19167
- fatigue154
- death127
- pyrexia114
- fall112
- malaise111
- weight increased106
- headache105
- infusion related reaction102
- nausea98
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 12 |
| 2011 | 21 |
| 2012 | 43 |
| 2013 | 74 |
| 2014 | 114 |
| 2015 | 101 |
| 2016 | 97 |
| 2017 | 84 |
| 2018 | 141 |
| 2019 | 158 |
| 2020 | 160 |
| 2021 | 313 |
| 2022 | 224 |
| 2023 | 154 |
| 2024 | 173 |
| 2025 | 112 |
| 2026 | 71 |
Recalls
1 FDA enforcement reports for this application.
Mar 14, 2014 · Class I · Terminated
Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vpriv (Velaglucerase Alfa)
2024 spending
$9.3M
Beneficiaries
24
285 claims
Per beneficiary
$386,843
$1,452.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,205,400 |
| 2021 | $8,478,535 |
| 2022 | $8,532,016 |
| 2023 | $9,262,628 |
| 2024 | $9,284,239 |
Part B: Vpriv (Velaglucerase Alfa) · HCPCS J3385
2024 spending
$32.7M
Beneficiaries
107
2,091 claims
Per beneficiary
$305,343
2024 ASP limit $368.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $25,304,812 |
| 2021 | $27,094,729 |
| 2022 | $28,849,851 |
| 2023 | $30,900,225 |
| 2024 | $32,671,660 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease.
Leonart LP, Fachi MM, Böger B, et al. · Ann Pharmacother 2023 · Meta-Analysis, Systematic Review
- Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
Zimran A, Elstein D, Gonzalez DE, et al. · Blood Cells Mol Dis 2018 · Clinical Trial, Phase III, Multicenter Study
- Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
Elstein D, Mellgard B, Dinh Q, et al. · Mol Genet Metab 2017 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E, Deroma L, Bembi B, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
Zimran A, Pastores GM, Tylki-Szymanska A, et al. · Am J Hematol 2013 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
Hughes DA, Gonzalez DE, Lukina EA, et al. · Am J Hematol 2015 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.